

PUBLIC SUMMARY DOCUMENT

Product: Hollister Hollihesive

Applicant: Hollister

Date of SPAP Meeting: 12 October 2021

1. Proposed Deletion on the Stoma Appliance Scheme

The applicant, Hollister, sought the deletion of the entire product range of Hollister Hollihesive (SAS Code 3530T) in subgroup 9(a) of the Stoma Appliance Scheme (the SchemSAS) Schedule, due to product being discontinued. The product is currently listed at a unit price of \$2.876, with a maximum monthly quantity of 30 units.

2. Substitute products

The nominated substitute product is Hollister Flextend (SAS Code 3558G) in the same subgroup. The product is currently listed at a unit price of \$2.876, with a maximum monthly quantity of 30 units.

Variant to be deleted

Product Code	Description
7700	skin barrier, 10cm x10cm

Nominated substitute – SAS Code 3558G

Product Code	Description
8800	stomahesive skin barrier, 10x10cm

3. Background

This product was first listed on the Scheme Schedule on 1 April 2011.

4. Clinical Place for the Product

The proposed substitute product provides an alternative for users requiring an adhesive barrier.

Financial Analysis

The substitute product is currently listed in subgroup 9(a) of the Scheme Schedule at the same cost and maximum monthly quantity. It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of deleting this product.

5. Panel Recommendation

The Panel recommended the deletion of the entire product range of Hollister Hollihesive (SAS Code 3530T) in subgroup 9(a) of the Scheme Schedule at the unit price of \$2.876, with a maximum monthly quantity of 30 units.

The Panel also noted that Hollister is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the date of the Panel's recommendation (12 October 2021) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

6. Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government. All Panel recommendations are subject to Cabinet/Ministerial approval.

7. Applicant's Comment

Hollister agree with the SPAP's recommendation.